Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol

• Main Authors: Patrik Nasr, Fredrik Iredahl, Nils Dahlström, Karin Rådholm, Pontus Henriksson, Gunnar Cedersund, Olof Dahlqvist Leinhard, Tino Ebbers, Joakim Alfredsson, Carl-Johan Carlhäll, Peter Lundberg, Stergios Kechagias, Mattias Ekstedt
• Format: Article
• Language: English
• Published: BMC 2021-04-01
• Series: BMC Gastroenterology
• Subjects: Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; T2DM; Cirrhosis; Biomarkers
• Online Access: https://doi.org/10.1186/s12876-021-01763-z

Abstract Background Non-alcoholic fatty liver disease (NAFLD) affects 20–30% of the general adult population. NAFLD patients with type 2 diabetes mellitus (T2DM) are at an increased risk of advanced fibrosis, which puts them at risk of cardiovascular complications, hepatocellular carcinoma, or liver failure. Liver biopsy is the gold standard for assessing hepatic fibrosis. However, its utility is inherently limited. Consequently, the prevalence and characteristics of T2DM patients with advanced fibrosis are unknown. Therefore, the purpose of the current study is to evaluate the prevalence and severity of NAFLD in patients with T2DM by recruiting participants from primary care, using the latest imaging modalities, to collect a cohort of well phenotyped patients. Methods We will prospectively recruit 400 patients with T2DM using biomarkers to assess their status. Specifically, we will evaluate liver fat content using magnetic resonance imaging (MRI); hepatic fibrosis using MR elastography and vibration-controlled transient elastography; muscle composition and body fat distribution using water-fat separated whole body MRI; and cardiac function, structure, and tissue characteristics, using cardiovascular MRI. Discussion We expect that the study will uncover potential mechanisms of advanced hepatic fibrosis in NAFLD and T2DM and equip the clinician with better diagnostic tools for the care of T2DM patients with NAFLD. Trial registration: Clinicaltrials.gov, identifier NCT03864510. Registered 6 March 2019, https://clinicaltrials.gov/ct2/show/NCT03864510 .